Evidence map›Paper›PMID 35431772›Full record

ArticleFrontiers in neuroscience2022

SARM1 Promotes Photoreceptor Degeneration in an Oxidative Stress Model of Retinal Degeneration.

Luke Gibbons, Ema Ozaki, Chris Greene, Anne Trappe, Michael Carty, Judith A Coppinger, Andrew G Bowie, Matthew Campbell, Sarah L Doyle

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. A Role for SARM1 in Photoreceptor Cell Death.Advances in experimental medicine and biology · 2025
    Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Luke GibbonsTrinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Ema OzakiTrinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Chris GreeneSmurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
Anne TrappeSchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Michael CartySchool of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
Judith A CoppingerSchool of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Andrew G BowieSchool of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
Matthew CampbellSmurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland.
Sarah L DoyleTrinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.
Trinity College Dublin · IERoyal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARM1 (sterile alpha and armadillo motif-containing protein) is a highly conserved Toll/IL-1 Receptor (TIR) adaptor with important roles in mediating immune responses. Studies in the brain have shown that SARM1 plays a role in induction of neuronal axon degeneration in response to a variety of injuries. We recently demonstrated that SARM1 is pro-degenerative in a genetic model of inherited retinopathy. This current study aimed to characterise the effect of SARM1 deletion in an alternative model of retinal degeneration (RD) in which the retinal pigment epithelium (RPE) fragments following administration of oxidising agent, sodium iodate (NaIO

Indexed as

caspase-3cell deathphotoreceptorsretinal degenerationSARM1sodium iodate

Identifiers

PMID35431772
PMCPMC9012108
OpenAlexW4220766035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.